University Clinical Hospital of Salamanca | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)	Hemic and Lymphatic Diseases, Neoplasms by Site, VEXAS syndrome, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, myelodysplastic syndrome, neoplasm	Active, not recruiting	Phase 2	2026-09-15		NCT06782373
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas	B-cell neoplasm, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, T-cell non-Hodgkin lymphoma, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenoma, diffuse large B-cell lymphoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, immune system disorder, immunoproliferative disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorder	Recruiting	Phase 1 / Phase 2	2026-08-19		NCT04104776
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis	Recruiting	Phase 3	2025-09-25		NCT06479135